Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Doximity
Historique des cours de bourse
Prix actuel de l'action	US$26.11
Plus haut sur 52 semaines	US$76.51
Plus bas sur 52 semaines	US$17.15
Bêta	1.25
Variation sur 1 mois	3.08%
Variation sur 3 mois	30.09%
Variation sur 1 an	-64.14%
Variation sur 3 ans	31.27%
Variation sur 5 ans	-69.67%
Évolution depuis l'introduction en bourse	-50.74%

Nouvelles et mises à jour récentes

Mise à jour du récit • Sep 05

DOCS: AI Monetization And Clinical Suite Adoption Will Support Higher Earnings Power

Analysts lifted their Doximity fair value estimate from about $36.89 to roughly $45.45, citing revised models that factor in a slightly higher assumed P/E multiple, modestly lower revenue growth, a small uptick in profit margin, and updated views on AI driven monetization following recent price target changes across the Street. Analyst Commentary Recent Street commentary on Doximity shows a wide range of views, but the common thread is that the latest quarter and early AI initiatives are front and center for valuation debates.

Mise à jour du récit • Aug 22

DOCS: AI Budget Share And Q1 AI Traction Will Drive Bullish Outlook

Analysts have lifted their Doximity price target from about $28.00 to roughly $29.78. This reflects updated models after Q1 results, differing views on AI monetization, and mixed opinions on how far current AI traction and pharma budget share can support growth amid rising competition and margin pressures.

Recent updates

Mise à jour du récit • Sep 05

DOCS: AI Monetization And Clinical Suite Adoption Will Support Higher Earnings Power

Mise à jour du récit • Aug 22

DOCS: AI Budget Share And Q1 AI Traction Will Drive Bullish Outlook

Mise à jour du récit • Aug 08

DOCS: AI Investment Year And Pharma Budget Share Will Shape Fairly Valued Outlook

Analysts have raised Doximity’s fair value estimate from $24.37 to $28.00, reflecting Street research that highlights solid recent results, early traction in AI search, and the potential for the company to capture a larger share of pharma marketing budgets, despite ongoing questions about competition and execution risk. Analyst Commentary Street research on Doximity is split, with some bullish analysts pointing to improving execution and AI traction, while more cautious voices focus on execution risk, competition in healthcare AI, and visibility on longer term growth.

Seeking Alpha • Aug 07

Doximity Jumps On Earnings: Explaining The Outsized Stock Move (Rating Upgrade)

Summary Doximity, Inc. is upgraded to buy as the narrative shifts from stagnation to credible reacceleration, driven by AI engagement and improved revenue guidance. Revenue grew 7% YoY to $156.6M, with FY27 guidance raised to $671–681M, while margins compressed due to intentional reinvestment in AI and sales. AI tools, especially Doximity Ask, are rapidly integrating into physician workflows, positioning DOCS for deeper engagement and future monetization opportunities. DOCS stock valuation sits at a discount to peers on earnings and EBITDA, with the upside hinging on AI-driven engagement translating into sustained revenue growth. Read the full article on Seeking Alpha

Mise à jour du récit • Jul 21

DOCS: Clinical AI Safety Leadership Will Support Higher Future Earnings Power

The analyst fair value estimate for Doximity has been reset from $55.00 to $36.89 after multiple firms trimmed price targets, citing concerns about slower core growth, heavier AI investment weighing on margins, and rising competitive and execution risks. Analyst Commentary Recent Street research on Doximity reflects a reset in expectations around growth, profitability, and competitive positioning, particularly as the company leans into heavier AI investment and faces questions about the durability of its core advertising business.

Mise à jour du récit • Jul 07

DOCS: AI Spending And Competitive Pressures Will Test Healthcare Moat And Reengagement Potential

Doximity's analyst price target has been trimmed as fair value and the assumed future P/E move lower, with analysts citing weaker revenue visibility, heavier AI spending, and rising competitive pressures around digital pharma marketing and healthcare AI tools. Analyst Commentary Recent Street research on Doximity points to a more cautious stance, with many firms cutting price targets and revisiting growth expectations after the latest earnings reports and long term guidance.

Mise à jour du récit • Jun 23

DOCS: AI Investment Year And Healthcare Moat Set To Support Reengagement

The updated Doximity analyst price target edges up slightly to $25.42, as analysts balance concerns about slower digital advertising growth, tougher competition, and heavier AI investment against a still supportive longer term rationale. This is reflected in a modestly higher fair value and P/E assumption.

Nouveau récit • Jun 13

High physician usership and impressive AI tools

What I like about Doximity is that there really is a very high viewership / user base of active practicing Physicians in the US and that is not invaluable and definitely could be monetized perhaps more efficiently. I also think that Doximity offers a lot of interesting tools for Physicians a lot of which you’re free and really marketed towards I think Physicians who are more in private practice.

Mise à jour du récit • Jun 07

DOCS: Healthcare Moat And AI Investment Year Will Drive Future Engagement

Analyst price targets for Doximity have been reset lower, with the internal fair value estimate moving from $37.77 to $25.15 as analysts factor in slower projected revenue growth, softer profit margins, and a reduced future P/E multiple amid industry wide concerns about digital ad spending, rising competition, and uncertain payoffs from heavier AI investment. Analyst Commentary Street research has turned more cautious on Doximity following its recent results and fiscal 2027 outlook, with many firms cutting price targets and, in several cases, downgrading ratings.

Mise à jour du récit • May 23

DOCS: Heavier AI Spending And Competition Will Drive A Cautious Bearish Outlook

Analysts cut the Doximity fair value estimate from $25.00 to $18.00, citing a wave of price target reductions and ratings downgrades that point to slower expected revenue growth, thinner margins, rising AI investment costs, and tougher digital advertising and healthcare IT competition. Analyst Commentary Street research around Doximity has shifted decisively more cautious, with a cluster of downgrades and lower price targets following the most recent earnings and long term outlook.

Mise à jour du récit • May 09

DOCS: AI Suite And Platform Stickiness Will Support Higher Future Earnings Power

Analysts trimmed their Doximity fair value estimate to $55.00 from $56.00, reflecting reduced revenue growth assumptions, partly offset by expectations for slightly higher profit margins and a marginally richer future P/E multiple following a series of recent price target cuts and mixed rating changes across the Street. Analyst Commentary Recent Street research on Doximity has been mixed, with a cluster of price target cuts and rating changes alongside a handful of more constructive views.

Mise à jour du récit • Apr 21

DOCS: Healthcare Moat And AI Tools Will Support Future Engagement

The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite. Analyst Commentary Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth.

Mise à jour du récit • Apr 07

DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement

The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.

Mise à jour du récit • Mar 24

DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook

Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.

Mise à jour du récit • Mar 09

DOCS: AI Tools And Share Buybacks Will Drive Shares Higher

Doximity's updated fair value estimate has decreased to $56.00 from $68.90, reflecting analysts' reduced price targets from several firms, alongside ongoing support for the company's AI tools and healthcare marketing position. Analyst Commentary Street research on Doximity has been mixed, but there is a clear cluster of bullish analysts who see support for the story in healthcare marketing, AI tools and the company’s position with U.S. physicians.

Mise à jour du récit • Feb 23

DOCS: AI Suite And Share Buybacks Will Shape A More Balanced Outlook

The analyst fair value estimate for Doximity has been revised to $25 from $50, reflecting a wave of reduced price targets across several firms, even as some analysts highlight potential from the company’s AI tools and broader healthcare marketing ecosystem. Analyst Commentary Recent research on Doximity shows a split tape, with some firms cutting price targets sharply while others highlight potential upside tied to the company’s tools and healthcare marketing position.

Mise à jour du récit • Feb 09

DOCS: Pharma Ad Shift And Share Buybacks Will Drive Shares Higher

Analysts have reduced their Doximity fair value estimate from about US$83 to roughly US$69. This reflects updated expectations for more moderate revenue growth, slightly lower profit margins and a reduced future P/E multiple, even as several firms highlight the company’s strong position in digital healthcare marketing and its expanding product tools.

Article d’analyse • Feb 06

Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%

To the annoyance of some shareholders, Doximity, Inc. ( NYSE:DOCS ) shares are down a considerable 27% in the last...

Mise à jour du récit • Jan 26

DOCS: Rebased Sentiment And Strong Moat Will Support Future Engagement

Narrative Update on Doximity The analyst fair value estimate for Doximity has been adjusted from US$65.25 to about US$63.57 as analysts factor in lower target prices, along with continued confidence in the company's moat, market share gains, and higher reported ROI compared with other digital healthcare marketing platforms. Analyst Commentary Recent research on Doximity highlights a mix of optimism and caution as analysts update ratings and price targets while reassessing growth, execution, and risk pricing.

Mise à jour du récit • Jan 11

DOCS: Rebased Sentiment And Budget Shifts Will Support Stronger Engagement

Our updated analyst price target framework for Doximity moves fair value from US$71.11 to US$65.25 as analysts recalibrate growth, discount rate and forward P/E assumptions, while still pointing to strengthening platform engagement and expanding tools such as OpenEvidence, as well as what several describe as a defensible competitive position in healthcare professional marketing. Analyst Commentary Recent Street research on Doximity reflects a mix of optimism around the core franchise and its tools such as OpenEvidence, alongside a more cautious reset on valuation and competitive risk.

Mise à jour du récit • Dec 26

DOCS: Budget Flush And Pharma Ad Shift Will Drive Shares Higher

We modestly raised our Doximity price target to $83.00 per share from $62.00, as analysts highlight improving long term growth visibility, accelerating video driven revenue momentum, and an increasingly compelling risk reward profile following the recent pullback, despite ongoing debate around pharma digital ad trends. Analyst Commentary Bullish analysts are increasingly highlighting Doximity as a high conviction idea following the post earnings selloff, pointing to a more attractive entry point relative to its vertical software peers.

Mise à jour du récit • Dec 12

DOCS: Budget Flush And Ad Shift Will Drive Shares Higher

Analysts have lifted their Doximity fair value estimate to $83.00 from $78.58, reflecting stronger expected revenue growth and improving long term growth visibility, which they believe more than offset lower margin assumptions and a higher required return. Analyst Commentary Bullish analysts highlight that the recent pullback in Doximity shares has created a compelling entry point, with the stock now trading at what they view as an unjustified discount to the broader vertical software peer group.

Article d’analyse • Nov 14

Doximity, Inc. (NYSE:DOCS) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

The Doximity, Inc. ( NYSE:DOCS ) share price has fared very poorly over the last month, falling by a substantial 26...

Mise à jour du récit • Nov 01

DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks

Analysts have modestly increased their price target for Doximity, raising the estimate from $70.72 to $71.11 per share. They cite stronger revenue momentum, which is supported by recent upgrades and expectations for higher provider-driven growth.

Mise à jour du récit • Oct 18

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Analysts have raised their price target for Doximity from $69.50 to $70.72. They cited slightly improved profit margin forecasts and increased confidence in the company’s platform engagement as advertising trends evolve.

Mise à jour du récit • Oct 04

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Doximity's analyst price target has increased from $68.67 to $69.50 per share. This change reflects analysts' positive view on strong business momentum, promising AI initiatives, and a conservative outlook for fiscal 2026 revenue growth.

Mise à jour du récit • Sep 13

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Doximity’s price target was raised modestly to $68.67 as analysts pointed to robust Q1 results, AI-driven strategy enhancements, and conservative guidance as drivers of sustained business momentum. Analyst Commentary Bullish analysts cite strong Q1 results and upwardly revised guidance as evidence of solid business momentum.

Article d’analyse • Sep 02

At US$67.94, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?

Doximity, Inc. ( NYSE:DOCS ) saw a significant share price rise of 32% in the past couple of months on the NYSE...

Article d’analyse • Aug 15

We Think Doximity's (NYSE:DOCS) Profit Is Only A Baseline For What They Can Achieve

NYSE:DOCS 1 Year Share Price vs Fair Value Explore Doximity's Fair Values from the Community and select yours When...

Mise à jour du récit • Aug 10

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Doximity’s fair value outlook has improved as reflected by a higher consensus price target, despite a notable contraction in net profit margin and a rising future P/E multiple signaling higher growth expectations. What's in the News Doximity provided revenue guidance for FY26 of $628–636 million and Q2 FY26 of $157–158 million.

Article d’analyse • Jul 08

Getting In Cheap On Doximity, Inc. (NYSE:DOCS) Is Unlikely

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...

Article d’analyse • Jun 23

With EPS Growth And More, Doximity (NYSE:DOCS) Makes An Interesting Case

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Article d’analyse • May 17

At US$52.56, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?

Let's talk about the popular Doximity, Inc. ( NYSE:DOCS ). The company's shares saw significant share price movement...

Rendement pour les actionnaires

	DOCS	US Healthcare Services	US Marché
7D	2.1%	1.5%	-0.2%
1Y	-64.1%	-17.7%	12.1%

Rendement vs Industrie: DOCS a sous-performé le secteur US Healthcare Services qui a rapporté -17.7 % au cours de l'année écoulée.

Rendement vs marché: DOCS a sous-performé le marché US qui a rapporté 12.1 % au cours de l'année écoulée.

Volatilité des prix

Is DOCS's price volatile compared to industry and market?
DOCS volatility
DOCS Average Weekly Movement	11.3%
Healthcare Services Industry Average Movement	10.4%
Market Average Movement	6.8%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	2.9%

Cours de l'action stable: Le cours de l'action de DOCS a été volatil au cours des 3 derniers mois par rapport au marché US.

Volatilité au fil du temps: La volatilité hebdomadaire de DOCS ( 11% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2010	880	Jeff Tangney	www.doximity.com

Doximity, Inc. exploite une plateforme numérique pour les professionnels de la santé aux États-Unis. Sa plateforme Doximity comprend un fil d'actualité personnalisé qui présente du contenu clinique et professionnel aux membres, qui propose des articles médicaux, des essais cliniques ou des résultats de recherche dans un format vidéo facile à consommer, des mises à jour professionnelles et des réalisations de leurs pairs et collègues, des discussions cliniques, des articles Op-Med à publier, et du contenu sponsorisé par des fabricants pharmaceutiques et des systèmes de santé. L'entreprise propose également des outils de gestion des flux de travail, notamment Ask, un assistant IA conforme à la norme HIPAA, qui permet d'accéder à des informations médicales fondées sur des données probantes et de les appliquer dans le cadre des flux de travail cliniques ; Scribe, un outil de documentation clinique conforme à la norme HIPAA et alimenté par l'IA ; des outils de télésanté pour les hôpitaux et les systèmes de santé ; et AMiON, un outil de planification des services de garde.

Doximity, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Doximity se comparent-ils à sa capitalisation boursière ?
DOCS statistiques fondamentales
Capitalisation boursière	US$4.65b
Bénéfices(TTM)	US$167.05m
Recettes(TTM)	US$655.57m

27.9x

Ratio P/E

7.1x

Ratio P/S

Le site DOCS est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
DOCS compte de résultat (TTM)
Recettes	US$655.57m
Coût des recettes	US$78.23m
Marge brute	US$577.34m
Autres dépenses	US$410.30m
Les revenus	US$167.05m

Derniers bénéfices déclarés

Jun 30, 2026

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	0.94
Marge brute	88.07%
Marge bénéficiaire nette	25.48%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de DOCS?

Voir les performances historiques et les comparaisons

Analyse de l'entreprise et données financières

Données	Dernière mise à jour (heure UTC)
Analyse de l'entreprise	2026/09/20 23:03
Cours de l'action en fin de journée	2026/09/18 00:00
Les revenus	2026/06/30
Revenus annuels	2026/03/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

Paquet	Données	Cadre temporel	Exemple de source américaine ^*
Finances de l'entreprise	10 ans	Compte de résultat Tableau des flux de trésorerie Bilan	Formulaire 10-K de la SEC Formulaire 10-Q de la SEC
Estimations consensuelles des analystes	+3 ans	Prévisions financières Objectifs de prix des analystes	Rapports de recherche des analystes Blue Matrix
Prix du marché	30 ans	Cours des actions Dividendes, scissions et actions	Données de marché ICE Formulaire S-1 de la SEC
Propriété	10 ans	Actionnaires principaux Délits d'initiés	Formulaire 4 de la SEC Formulaire 13D de la SEC
Gestion	10 ans	L'équipe dirigeante Conseil d'administration	Formulaire 10-K de la SEC Formulaire SEC DEF 14A
Principaux développements	10 ans	Annonces de l'entreprise	Formulaire 8-K de la SEC

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés^.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Doximity, Inc. est couverte par 25 analystes. 20 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

Analyste	Institution
Vikram Kesavabhotla	Baird
Glen Santangelo	Barclays
Nisala Weerasuriya	Berenberg

Doximity (DOCS) Aperçu de l'action

Récompenses

Analyse des risques

Analyst Price Targets

DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks

Digital Transformation And Telehealth Will Revolutionize Healthcare Collaboration

Privacy Rules Will Squeeze Margins While Tools Will Support Recovery

Top Community Narratives

High physician usership and impressive AI tools

Top Community Narratives

High physician usership and impressive AI tools

Top Analyst Narratives

DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks

Digital Transformation And Telehealth Will Revolutionize Healthcare Collaboration

Privacy Rules Will Squeeze Margins While Tools Will Support Recovery

Doximity, Inc. Concurrents

Waystar Holding

GoodRx Holdings

HealthStream

Phreesia

Historique des prix et performances

Nouvelles et mises à jour récentes

Bernstein Litowitz Berger & Grossmann LLP Announces Filing of Securities Class Action Lawsuit Against Doximity Inc

Doximity’s Former Revenue Chief Fined $500,000 Over Insider Trading Judgment

DOCS: AI Monetization And Clinical Suite Adoption Will Support Higher Earnings Power

DOCS: AI Budget Share And Q1 AI Traction Will Drive Bullish Outlook

Investor sentiment improves as stock rises 16%

Doximity Raises Full-Year 2027 Outlook After Q1 Surge in AI-Driven Revenue

Recent updates

Bernstein Litowitz Berger & Grossmann LLP Announces Filing of Securities Class Action Lawsuit Against Doximity Inc

Doximity’s Former Revenue Chief Fined $500,000 Over Insider Trading Judgment

DOCS: AI Monetization And Clinical Suite Adoption Will Support Higher Earnings Power

DOCS: AI Budget Share And Q1 AI Traction Will Drive Bullish Outlook

Investor sentiment improves as stock rises 16%

Doximity Raises Full-Year 2027 Outlook After Q1 Surge in AI-Driven Revenue

DOCS: AI Investment Year And Pharma Budget Share Will Shape Fairly Valued Outlook

Doximity, Inc. Provides Earnings Guidance for Its Fiscal Second Quarter Ending September 30, 2026; Updates Earnings Guidance for Its Fiscal Year Ending March 31, 2027

New minor risk - Profit margin trend

First quarter 2027 earnings: Revenues exceed analysts expectations while EPS lags behind

Doximity Jumps On Earnings: Explaining The Outsized Stock Move (Rating Upgrade)

DOCS: Clinical AI Safety Leadership Will Support Higher Future Earnings Power

Doximity, Inc. to Report Q1, 2027 Results on Aug 06, 2026

Doximity, Inc., Annual General Meeting, Aug 27, 2026

DOCS: AI Spending And Competitive Pressures Will Test Healthcare Moat And Reengagement Potential

Law Firm Opens Governance Probe Into Doximity After 49.5% Year-To-Date Decline

Doximity Cut to Underperform as AI Pivot Poses Execution and Margin Challenges

Doximity, Inc.(NYSE:DOCS) dropped from Russell 2500 Growth Benchmark

DOCS: AI Investment Year And Healthcare Moat Set To Support Reengagement

High physician usership and impressive AI tools

Doximity Stock Falls 23% After Earnings Miss Triggers Legal and Analyst Scrutiny

DOCS: Healthcare Moat And AI Investment Year Will Drive Future Engagement

Doximity Revenue Meets Estimates as AI Investments Weigh on Growth and Profit Outlook

DOCS: Heavier AI Spending And Competition Will Drive A Cautious Bearish Outlook

Consensus EPS estimates fall by 30%

Doximity, Inc. Provides Earnings Guidance for the Fiscal First Quarter Ending June 30, 2026 and Fiscal Year Ending March 31, 2027

Full year 2026 earnings: EPS misses analyst expectations

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

DOCS: AI Suite And Platform Stickiness Will Support Higher Future Earnings Power

Doximity, Inc. to Report Q4, 2026 Results on May 13, 2026

DOCS: Healthcare Moat And AI Tools Will Support Future Engagement

Investor sentiment improves as stock rises 17%

DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement

DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook

DOCS: AI Tools And Share Buybacks Will Drive Shares Higher

DOCS: AI Suite And Share Buybacks Will Shape A More Balanced Outlook

Investor sentiment deteriorates as stock falls 26%

DOCS: Pharma Ad Shift And Share Buybacks Will Drive Shares Higher

Price target decreased by 26% to US$46.90

Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $500 million worth of its shares.

DOCS: Rebased Sentiment And Strong Moat Will Support Future Engagement

Doximity, Inc. to Report Q3, 2026 Results on Feb 05, 2026

Now 20% undervalued after recent price drop

DOCS: Rebased Sentiment And Budget Shifts Will Support Stronger Engagement

Doximity, Inc. Reaches Settlement Agreement Resolving Pending Securities Litigation Claims

DOCS: Budget Flush And Pharma Ad Shift Will Drive Shares Higher

DOCS: Budget Flush And Ad Shift Will Drive Shares Higher

Independent Director notifies of intention to sell stock